The history of selective COX-2 inhibitors was nearly derailed in 2004 when Merck voluntarily pulled rofecoxib (Vioxx) from global shelves after trials proved it doubled heart attack and stroke rates. That crisis triggered immediate scrutiny of Celebrex, prompting federal regulators to demand exhaustive safety data. The medical community spent over a decade searching for definitive answers regarding celecoxib's safety profile.
The landmark PRECISION trial, published in The New England Journal of Medicine, randomized more than 24,000 arthritis patients across a decade to compare celecoxib directly against naproxen and ibuprofen. The results altered cardiology perspectives: moderate doses of celecoxib (averaging 100 mg to 200 mg daily) proved non-inferior to traditional NSAIDs regarding major adverse cardiovascular events (MACE), cardiovascular deaths, and nonfatal strokes. The study confirmed that cardiovascular hazard is an inherent class-wide characteristic of all systemic NSAIDs rather than an isolated flaw in celecoxib.
Yet research continues to uncover nuanced risks. Investigations highlighted by patient advocacy network CreakyJoints and researchers at Vanderbilt University showed that prolonged celecoxib exposure can elevate heart valve disease risk. The mechanism ties back to the drug's interaction with cadherin-11, a cell-surface protein in aortic valves that can spur calcification and structural stiffening under sustained high dosages. Cardiologists closely screen patients with pre-existing aortic stenosis or advanced congestive heart failure before recommending long-term celecoxib therapy.
